Amgen’s head of R&D, Sean Harper, announced he is stepping down from the big biotech to pursue new opportunities in startups and early-stage companies.
Harper has led Amgen’s research work since taking over for Roger Perlmutter in 2012, inheriting a $3-billion-plus research budget, and helped guide the company to new product approvals in oncology, neuroscience, cardiovascular and kidney disease. He has spent the past 16 years at the company, joining as VP of development in 2002 from Merck Research Laboratories.
Amgen’s senior vice president of translational sciences and oncology, David Reese, will take over as executive VP of R&D, effective immediately, the company said in a statement. After joining Amgen in 2005, Reese has held roles in its development and medical sciences departments, and served as head of discovery research. Harper will stay on for a time to help with the transition.
In addition, the company’s executive VP of global commercial operations, Anthony Hooper, announced his retirement. Murdo Gordon, who recently left Bristol-Myers Squibb as commercial head, will take over in September.
“I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each bringing their own vital experiences and skills,” said Amgen Chairman and CEO Robert Bradway. “They leave the company having established strong foundations within Research and Development and Global Commercial Operations for the future.”
Analysts at Jefferies said in a note to clients: “More exec changes in the industry. Neutral impact to Amgen for Street perspective.” The firm says that Harper “was fairly well-regarded in the biotech community given advancement of numerous drugs (PCSK9, CGRP, Bone health) and recently well known for his bullishness on bi-specifics instead of CAR-T.”
In May, Amgen and Novartis ushered in a new class of migraine drugs with the FDA’s approval of Aimovig, a calcitonin gene-related peptide receptor with blockbuster hopes. That landmark could prove important as the company begins to see new biosimilar competition for its tentpole products, such as Neulasta.
By Conor Hale
Source: Fierce Biotech
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.